Part 2: Exploring the potential for collaboration to trigger new initiatives and value-for-money in Canada’s healthcare system. Part 2 of a two-part series on the benefits of public-private collaboration. In part one of this series we focused on the arguments calling for collaboration between all levels of government together with private plan sponsors, insurers and […]
Part 1: Public-Private collaboration is overdue Part 1 of a two-part series on the benefits of public-private collaboration in sparking innovation and competitive advantage. Our country’s competitive labour advantage has traditionally relied upon the value of the Canadian dollar and the comparatively low cost of our social healthcare system. But our defences are buckling and […]
What has become transparent as a result of The Transparent Drug System for Patients Act (TDSPA)is employers’ immediate need for collective purchasing power in the face of the dual pricing system that is falling into place. What does this mean? Earlier this month, we first saw a drug price list issued to pharmacies that confirmed […]
WHAT IS BECOMING “TRANSPARENT,” IF WE ARE TO USE THE term from the Ontario government’s new drug legislation, is that private payers—whether employers, individual policy owners or uninsured cash-paying consumers—may be on their own to negotiate future drug prices. When The Transparent Drug System for Patients Act, 2006 was first introduced, the government’s intention was […]